About GenOway
GenOway is a publicly listed company based in Lyon (France) founded in 1999. Provider of transgenic rodent models and customized cell lines for preclinical development. GenOway has raised $11.55 million across 5 funding rounds from investors including Siparex, European Union and Eurostars. The company has 143 employees. GenOway has completed 1 acquisition, including Axenis. GenOway offers products and services including Humanized Mice, Cell Lines, Knockout Models, and Customized Models. Its focus areas include Life Sciences, Genomics, Genomics Research and Research Models.
Company details
GenOway was founded in 1999 and is based in Lyon, France. Operations center on the biotechnology sector, where transgenic mouse and rat models, along with customized cell lines, are created using techniques such as homologous recombination, CRISPRCas, FLEX, TET, and IRES Rosa 26Hprt. Knockout genes and point mutations are incorporated to address needs in neuroscience, immunology, metabolism, cardiovascular disorders, and cancer research.
- Headquarters Lyon, France
- Employees 143
- Stage Public
- SectorsHealthcare
- Website genoway.com
- Social LinkedIn X
- Legal Name Genoway Sa
- Annual Revenue$24.63 M (USD)-5as on Dec 31, 2025
- Net Profit$1.09 M (USD)-49.32as on Dec 31, 2025
- EBITDA-$819 K (USD)-753.74as on Dec 31, 2025
- Total Equity Funding$11.55M (USD)
in 5 rounds
- Latest Funding Round$280.38K (USD), Grant
Jan 2020
- InvestorsSiparex
& 5 more
- Employee Count143
- Investments & Acquisitions
Products & Services of GenOway
GenOway offers a comprehensive portfolio of products and services, including Humanized Mice, Cell Lines, Knockout Models, and Customized Models.
Genetically modified mice for in vivo efficacy and safety testing
Modified cell lines for tumor growth and mechanistic studies
Mice and rats with targeted gene knockouts for research purposes
Bespoke genetically modified models for specific scientific questions
Funding Insights of GenOway
GenOway has successfully raised a total of $11.55M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $280.38 thousand completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.55M
- Total Rounds 5
- Last Round Grant — $280,382
- First Round $6.65M
(Apr 2003)
- Investors Count 6
All 5 funding rounds of GenOway with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $280,382 | Grant | – | – | |
| Feb 2016 | Grant | – | – | ||
| Mar 2014 | $21,429 | Grant | – | – | |
| Sep 2004 | $4.9M | Series B | – | – | |
| Apr 2003 | $6.65M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in GenOway
GenOway has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Siparex, European Union and Eurostars.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are focused on growth stage companies. | 1977 | siparex.com | Paris, France | |
| dassault-developpement.fr | ||||
Kreaxi is engaged in equity financing for innovative startups. | kreaxi.com | Limonest, France | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
| eurostars-eureka.eu |
Investor details for GenOway
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GenOway
20 people are tracked at GenOway (9 in leadership, 11 in team); the tracked headcount is 143.
| Name | Role | Group |
|---|---|---|
Estelle Suaud Lefebvre | Chief Commercial Officer (cco) | Leadership |
Frederic Putinier | Directeur Des Opérations / COO | Leadership |
Maroun Karam | Head Of CRO Business Development | Leadership |
Benjamin Bruneau | Chief Financial Officer | Leadership |
Alexandre Fraichard | Chief Executive Officer | Leadership |
Yacine Cherifi | VP Technology Ansd Scientific Operations | Leadership |
Kader Thiam | Senior Vice President Discovery - Preclinical Models & Services | Leadership |
Fabiane Sônego | Director - Preclinical Models & Services | Leadership |
Florent Pons | Chief Marketing Officer | Leadership |
Florent Creusat | Associate Program Manager In R&d | Team |
Cyrielle Chabrier | Directrice Des Ressources Humaines | Team |
Marième Ndjim | Scientific Business Developer | Team |
Vinciane Vandenbussche | Assistante De Direction Générale | Team |
Benoit F. | Key Account Manager | Team |
Coraline Tissot | Responsable RH | Team |
Chloé Albert Vega | Scientific Business Developer | Team |
Sarah Duponchel | R&d Manager In Gene Editing | Team |
Hien Dang | Recruitment Manager | Team |
Ju-I Pan | Responsable Des Achats | Team |
José Viñuelas | Manager / Team Leader R&d, Biologie Moléculaire & Multiomique | Team |
Complete people profiles for GenOway
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of GenOway
GenOway is a publicly listed company on the EURONEXT with ticker symbol ALGEN in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 May 2007
- Listed onEuronext: ALGEN
- Listed entitygenOway SA
- Exchange sectorHealth technology
- ISINFR0004053510
- Share price2.24 EUR · 2026-10-14
- Market capitalisation27,868,077.00 EUR
- EPS (diluted, trailing year)-0.17 EUR
- Volume (last session)1
Financials of GenOway
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 21.0M EUR | 927,750 EUR | -697,020 EUR |
| 2024 | 22.1M EUR | 1.8M EUR | 106,620 EUR |
| 2023 | 20.1M EUR | 1.6M EUR | -961,940 EUR |
| 2022 | 17.1M EUR | 777,750 EUR | 93,650 EUR |
| 2021 | 14.0M EUR | -322,600 EUR | -2.7M EUR |
Detailed financial statements for GenOway
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GenOway
GenOway has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Axenis.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Chimeric in-vivo mouse models for biomedical research are developed. | axenis.fr | Paris, France | 2010 | Sep 2018 | •••• |
Complete acquisition details for GenOway
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of GenOway
5 dated milestones of GenOway across 21 years, from founding to its latest funding, stage changes and deals.
- Founded GenOway is founded.
- Funding First funding round of $6.6M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Axenis.
- Funding Latest funding round, Grant, of $280K.
Web traffic of GenOway
The website of GenOway (genoway.com) receives about 10K visits a month.
- Monthly visits10K
▼ 12.8% vs previous month
Websites whose visitors overlap most with GenOway. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| genetargeting.com | 100% | 3.3K | #5,558,610 | View details | |
aalas.org | aalas.org | 82% | #1,122,428 | – | |
aaalac.org | aaalac.org | 82% | #1,318,924 | – | |
emmanet.org | emmanet.org | 82% | – | ||
| biocytogen.com | 81% | 23.6K | #1,249,047 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 24 similar websites and full traffic analytics for GenOway
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 24 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genoway
Complete news archive for GenOway
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GenOway
GenOway was founded in 1999 and raised its 1st funding round 4 years after it was founded.
GenOway is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
GenOway is a funded company, having raised a total of $11.55M across 5 funding rounds to date. The company's 1st funding round was a Series A of $6.65M, raised on Apr 2003.
GenOway has 143 employees.
Annual revenue of GenOway is $24.63M as on Dec 31, 2025.
GenOway was founded in 1999 and is based in Lyon, France. Operations center on the biotechnology sector, where transgenic mouse and rat models, along with customized cell lines, are created using techniques such as homologous recombination, CRISPRCas, FLEX, TET, and IRES Rosa 26Hprt. Knockout genes and point mutations are incorporated to address needs in neuroscience, immunology, metabolism, cardiovascular disorders, and cancer research.
GenOway offers Humanized Mice, Cell Lines, Knockout Models, and Customized Models.
Yes, GenOway is publicly traded on EURONEXT under the ticker symbol ALGEN.
GenOway has made 1 acquisition, including Axenis.
GenOway has 6 investors. Key investors include Siparex, European Union, Eurostars, CDC Entreprises Innovation, and Dassault Developpement.